Iron supplements near duodenum model

Iron Bisglycinate vs Ferrous Sulfate: Which Is Right for You?

For most people with confirmed iron deficiency who can tolerate standard therapy, ferrous sulfate is the evidence-backed, low-cost first line. For those who experience GI side effects that derail adherence, ferrous bisglycinate offers a gentler alternative with clinical trial support at matched elemental doses.

  • Ferrous sulfate: The long-standing clinical standard. Largest evidence base, lowest cost, widely available over the counter. A standard ferrous sulfate 325 mg tablet contains about 20% elemental iron by weight.
  • Ferrous bisglycinate: A glycine-chelated form designed for better GI tolerability. Trial data show noninferiority to ferrous sulfate at matched elemental doses in some populations, particularly in pregnancy.
  • Key caveat: Dose equivalence matters. A lower-dose bisglycinate product is not automatically equivalent to a higher-dose ferrous sulfate regimen. Always compare elemental iron, not total chelate weight.

Start with ferrous sulfate using alternate-day dosing and vitamin C pairing. If GI intolerance persists after two to four weeks, switch to ferrous bisglycinate at a matched elemental dose. If oral therapy fails entirely, escalate to intravenous iron under clinical supervision.

Table of Contents

How do iron bisglycinate and ferrous sulfate compare across key dimensions?

The five dimensions below cover what most readers need to decide between these two formulations.

Dimension Ferrous Sulfate Ferrous Bisglycinate
Absorption / bioavailability Good; standard nonheme absorption via DMT1 Chelation may protect iron from dietary inhibitors; bioavailability advantage is context-dependent
Efficacy (Hb / ferritin) Strong RCT evidence for raising hemoglobin and ferritin Noninferior at matched elemental doses in key trials; lower doses may underperform
Elemental dose equivalence 325 mg tablet ≈ 65 mg elemental iron Label often states chelate weight; check supplement facts for elemental iron content
GI side effects / tolerability Higher rate of constipation, nausea, dark stools Fewer GI complaints in several trials at matched doses
Cost / availability Low cost; widely available at pharmacies and online Typically several times more expensive per dose; available at health retailers and online

Bottom line by dimension:

  • Absorption: Bisglycinate’s chelation can shield iron from phytates and polyphenols, but the advantage depends on the food matrix and formulation. Not universally superior.
  • Efficacy: Both forms raise ferritin and hemoglobin effectively when dosed at equivalent elemental amounts. The Cambodia RCT showed that 18 mg bisglycinate did not match 60 mg ferrous sulfate, underscoring that bioavailability gains do not overcome large dose gaps.
  • Tolerability: Bisglycinate’s clearest advantage. Fewer GI events translate directly to better adherence, which drives outcomes.
  • Cost: Ferrous sulfate wins decisively. Clinical commentary notes the cost premium for bisglycinate often lacks added clinical benefit for people who tolerate sulfate.

How does iron absorption work, and why does formulation matter?

Iron enters the body almost entirely through the duodenum. Nonheme iron, the form in both ferrous sulfate and ferrous bisglycinate, must be reduced to the ferrous (Fe²⁺) state before the DMT1 transporter on enterocyte brush-border membranes can carry it into the cell. Once absorbed, iron is either stored as ferritin within the enterocyte or exported into circulation via ferroportin. Hepcidin, a liver-produced hormone, regulates this export: high hepcidin closes ferroportin channels and blocks iron release, which is why dosing strategy matters as much as formulation choice.

Chelation changes the picture in the stomach and upper gut. In ferrous bisglycinate, iron is bound to two glycine molecules, forming a stable chelate. This structure resists reacting with dietary inhibitors in the gut lumen, such as phytates, polyphenols, and calcium, that would otherwise bind free iron and render it unabsorbable. Research on iron chelates confirms that chelation can protect iron from these inhibitors and may improve bioavailability and tolerability in specific formulations. Ferrous sulfate, by contrast, releases free iron ions in the stomach, which react readily with food components and can irritate the gut lining.

Factors that enhance or inhibit nonheme iron absorption:

  • Enhancers: Vitamin C (ascorbic acid) is the most potent dietary enhancer; it reduces Fe³⁺ to Fe²⁺ and chelates iron to keep it soluble. The meat factor (MFP) from animal protein also enhances absorption.
  • Inhibitors: Phytates (whole grains, legumes), polyphenols (tea, coffee, red wine), calcium (dairy, supplements), and certain medications all reduce absorption of free ferrous ions.
  • Drug interactions: Proton pump inhibitors reduce gastric acidity and can impair ferrous sulfate absorption more than chelated forms.

Dietary factors influencing iron absorption are well-documented and apply to both formulations, though chelation partially buffers bisglycinate from inhibitor effects.

Simplified absorption pathway:

  1. Stomach: acid environment reduces Fe³⁺ to Fe²⁺; chelate structure in bisglycinate resists inhibitor binding
  2. Duodenum: DMT1 transporter moves Fe²⁺ into enterocytes
  3. Enterocyte: iron stored as ferritin or exported via ferroportin into blood
  4. Liver: hepcidin levels regulate how much iron enters circulation; high hepcidin after a dose suppresses next-dose absorption (the rationale for alternate-day dosing)

What you need to know about ferrous sulfate

Ferrous sulfate is the clinical gold standard for oral iron therapy. It has the largest evidence base of any oral iron formulation, guideline backing from major health bodies, and a cost profile that makes it accessible without a prescription. A standard 325 mg ferrous sulfate tablet contains approximately 65 mg of elemental iron. Liquid formulations and lower-dose tablets (e.g., 200 mg ≈ 40 mg elemental) are also available for dose titration.

Typical adult regimens:

  1. Alternate-day dosing: 60–120 mg elemental iron every other day, which reduces hepcidin-mediated suppression and improves fractional absorption
  2. Daily dosing: 60–200 mg elemental iron per day in divided doses for more severe deficiency under clinical guidance
  3. Pregnancy: 60 mg elemental iron daily is a common supplementation target, though individual needs vary

Efficacy: Systematic reviews consistently place ferrous sulfate as the reference standard against which other oral iron forms are measured. It reliably raises hemoglobin and ferritin in iron-deficiency anemia (IDA) across diverse populations. A broad review of oral iron formulations confirms ferrous salts as the mainstay of first-line therapy, noting that newer formulations offer tolerability advantages for some but at higher cost and with a smaller evidence base.

Common GI side effects:

  • Constipation (most frequently reported)
  • Nausea and stomach cramping, especially on an empty stomach
  • Dark or tarry stools (expected; not harmful)
  • Metallic taste

These effects are dose-dependent. Splitting the dose, taking it with a small amount of food, or switching to alternate-day dosing reduces their frequency without meaningfully sacrificing efficacy.

When ferrous sulfate is the right choice:

  • First-line treatment for confirmed IDA in adults who have not previously experienced GI intolerance
  • Cost-sensitive situations where a 3–5x price premium for chelated iron is not justified
  • Settings where rapid repletion is needed and a higher elemental dose is required
  • When a clinician has prescribed a specific elemental iron target that a standard ferrous sulfate tablet can meet precisely

What you need to know about ferrous bisglycinate

Pouring bisglycinate powder into capsule

Ferrous bisglycinate, also called ferrous bisglycinate chelate, is iron bound to two glycine amino acid molecules. The chelate structure is the defining feature: it keeps iron stable in the gut lumen, reduces direct contact between free iron ions and the intestinal wall, and partially shields iron from dietary inhibitors. The result, in several clinical trials, is fewer GI complaints at matched elemental doses compared to ferrous sulfate.

Typical elemental doses in retail products and trials:

  1. Retail capsules commonly provide 18–28 mg elemental iron per serving (though the label may state the total chelate weight, which is higher)
  2. The pregnancy RCT used elemental iron doses of bisglycinate and ferrous sulfate in a ratio of approximately half bisglycinate to sulfate
  3. The Cambodia trial compared a significantly lower elemental iron dose of bisglycinate to a higher dose of ferrous sulfate

Key trial headlines:

  • At 25 mg bisglycinate versus 50 mg ferrous sulfate, a randomized trial in pregnant women found noninferiority for preventing iron deficiency and anemia, with fewer GI complaints in the bisglycinate group. This is the strongest evidence for bisglycinate’s tolerability advantage at a near-matched dose.
  • At 18 mg bisglycinate versus 60 mg ferrous sulfate, the Cambodia trial found bisglycinate did not match sulfate for raising ferritin. The dose gap was too large for bioavailability gains to compensate.

When bisglycinate is the right choice:

  • GI intolerance to ferrous sulfate that compromises adherence
  • Pregnancy, where tolerability directly affects whether supplementation continues
  • People who have stopped iron therapy previously due to side effects
  • Inflammatory bowel disease, where free iron in the gut may worsen symptoms (managed with a specialist)

Limitations to keep in mind:

  • Higher cost per dose than ferrous sulfate
  • Variable elemental iron labeling across brands; always check the supplement facts panel for elemental iron, not just the chelate weight
  • Advantages are formulation- and context-dependent; one AJCN study found no advantage for bisglycinate as an iron fortificant in certain food matrices

For readers choosing plant-based iron supplements, bisglycinate is often the preferred chelated form because plant-heavy diets are high in phytates and polyphenols, the exact inhibitors chelation helps counter.

What do the trials and systematic reviews actually show?

The evidence is mixed, and the pattern is consistent: bisglycinate is noninferior to ferrous sulfate when elemental doses are matched or close; it underperforms when its elemental dose is substantially lower. GI tolerability favors bisglycinate in most head-to-head trials.

Trial / Review Population Doses Compared Primary Outcome Ferritin / Hb Result Tolerability
Pregnancy RCT (PubMed 24152889) Pregnant women 25 mg bisglycinate vs 50 mg ferrous sulfate Iron deficiency / anemia prevention Noninferior for ID and IDA rates Fewer GI complaints with bisglycinate
Cambodia RCT (PubMed 37271416) 480 Cambodian women 18 mg bisglycinate vs 60 mg ferrous sulfate vs placebo Ferritin increase at 12 weeks Ferritin higher in sulfate group; bisglycinate not noninferior Not the primary focus; gut inflammation markers reported
PMC Review (PMC11367235) Multiple populations Various Efficacy and tolerability synthesis Ferrous salts remain reference standard Chelated forms show tolerability advantage for some
AJCN Fortification Study Fortification context Bisglycinate vs sulfate as food fortificants Iron status from fortified food No advantage for bisglycinate as fortificant Not applicable

What the evidence means in practice:

The pregnancy trial is the most clinically relevant for the tolerability argument: half the elemental dose of bisglycinate matched the full dose of ferrous sulfate for preventing deficiency, with better GI outcomes. The Cambodia trial is the most important caution: 18 mg bisglycinate could not match 60 mg ferrous sulfate in an iron-replete population, where the absolute benefit of any supplementation is smaller and dose differences are amplified.

A broad systematic review of oral iron formulations reinforces that ferrous salts remain the evidence-dense first line, while chelated forms offer a targeted tolerability advantage. The AJCN fortification data06895-8/fulltext) adds an important nuance: bisglycinate’s advantages do not hold universally across every delivery matrix.

Evidence selection note: The trials summarized here are randomized controlled trials or systematic reviews identified from PubMed and clinical nutrition journals. Key limitations include heterogeneous dosing protocols across trials, variation in baseline iron status (iron-replete vs. iron-deficient populations), and differences in trial duration and primary endpoints.

What do the trials and systematic reviews actually show? — overview diagram

How should you dose iron supplements for the best results?

The single most impactful practical shift in oral iron therapy over the last decade is dosing strategy, specifically alternate-day dosing, rather than simply switching formulations. This applies to both ferrous sulfate and bisglycinate.

Convert to elemental iron first. Before comparing products or doses, identify the elemental iron content on the supplement facts panel:

  • Ferrous sulfate 325 mg ≈ 65 mg elemental iron
  • Ferrous sulfate 200 mg ≈ 40 mg elemental iron
  • Ferrous bisglycinate: the label may state “ferrous bisglycinate 126 mg” but deliver only 25 mg elemental iron; always check the supplement facts panel

Administration strategies:

  • Alternate-day dosing: Taking iron every other day allows hepcidin levels to fall between doses, increasing fractional absorption on the next dose. This strategy improves tolerability and absorption efficiency across both formulations.
  • Vitamin C pairing: Taking 100–200 mg of ascorbic acid with each iron dose enhances absorption by reducing Fe³⁺ to Fe²⁺ and countering inhibitors. This is especially useful with ferrous sulfate taken on an empty stomach.
  • Timing relative to meals: Iron absorbs best on an empty stomach, but GI side effects are more common in that setting. Taking it 30–60 minutes before a meal balances absorption and tolerability.
  • Separation from inhibitors: Space iron at least two hours from calcium supplements, antacids, and high-phytate foods. Separate from coffee and tea by at least one hour.
  • Drug interactions: Levothyroxine, tetracyclines, fluoroquinolones, and bisphosphonates all bind iron in the gut. Take iron at least two to four hours apart from these medications.

Pro Tip: Run a four-week tolerability trial before switching formulations. Start ferrous sulfate at the lowest effective elemental dose (40–65 mg) on alternate days with vitamin C. If GI symptoms persist at week four, switch to ferrous bisglycinate at a matched elemental dose. If oral therapy fails after eight weeks of consistent use, discuss intravenous iron with your clinician.

For readers managing multiple supplements, vitamin B12 alongside iron addresses the fatigue and neurological symptoms that sometimes accompany iron deficiency, since both deficiencies can coexist.

What are the side effects, safety risks, and drug interactions?

GI symptoms are the primary tolerability difference between these two formulations. Bisglycinate generally causes fewer GI events at matched elemental doses, and that difference in tolerability is what drives adherence and, ultimately, clinical outcomes.

Common side effects (both formulations, more frequent with ferrous sulfate):

  • Constipation
  • Nausea and stomach cramping
  • Dark or black stools (expected; not a safety concern)
  • Metallic taste
  • Heartburn or reflux

Less common but important safety considerations:

  • Iron overload: People with hemochromatosis, thalassemia, or other iron-loading conditions should not take iron supplements without medical supervision. Excess iron is toxic.
  • Inflammatory conditions: In people with inflammatory bowel disease, free iron from ferrous sulfate can shift the gut microbiome and worsen symptoms in some models. Chelated forms or IV iron, managed with a specialist, are often preferable.
  • Active infection: High-dose iron supplementation during active bacterial infection may worsen outcomes; consult a clinician before starting supplementation if infection is present.

Drug interactions requiring separation:

  • Levothyroxine: Iron chelates thyroid hormone in the gut; separate by at least four hours
  • Tetracyclines and fluoroquinolones: Iron reduces antibiotic absorption; separate by two to four hours
  • Bisphosphonates (e.g., alendronate): Iron impairs absorption; separate by at least two hours
  • Proton pump inhibitors: Reduce gastric acidity, impairing ferrous sulfate absorption more than chelated forms; consider bisglycinate if a PPI cannot be stopped

When to seek medical care: Seek clinical evaluation if you develop severe abdominal pain, vomiting blood, or signs of iron toxicity (dizziness, rapid heartbeat, pale skin). Intravenous iron is indicated for severe symptomatic anemia, confirmed malabsorption syndromes, or failure of oral therapy after an adequate trial. A review of oral iron formulations notes that sustained adherence over several months is what defines effective oral iron therapy; GI tolerability is often the deciding factor in whether that adherence is achievable.

Which iron supplement is right for your situation?

Four common scenarios, four direct recommendations:

  • Newly diagnosed iron-deficiency anemia, no prior GI issues: Start with ferrous sulfate at 40–65 mg elemental iron on alternate days. It is inexpensive, evidence-dense, and effective.
  • Mild deficiency with GI sensitivity or prior intolerance: Switch to ferrous bisglycinate at a matched elemental dose (typically 25–28 mg elemental per dose). Confirm elemental iron on the label.
  • Pregnancy: Ferrous bisglycinate at 25 mg elemental iron is a reasonable first choice given the trial evidence for noninferiority compared to 50 mg ferrous sulfate, with fewer GI complaints. Discuss with your OB or midwife. Readers comparing prenatal vitamin formulations that include iron will find bisglycinate increasingly common in quality prenatal products.
  • Cost-constrained: Ferrous sulfate with alternate-day dosing and vitamin C pairing delivers strong clinical outcomes at a fraction of the cost of chelated forms. The cost-benefit evidence supports this approach for people who tolerate it.

Decision-flow questions:

  • Has iron deficiency been confirmed by a blood test (ferritin, hemoglobin, CBC)? If not, get tested before supplementing.
  • How severe is the deficiency? Mild deficiency may respond to lower doses; IDA typically requires 60–120 mg elemental iron daily or alternate-day.
  • Have you tried ferrous sulfate before? If yes, did GI side effects cause you to stop? If yes, bisglycinate is the next step.
  • Do you need rapid repletion (symptomatic anemia, pre-surgery)? Higher elemental doses and daily dosing may be required; discuss with a clinician.
  • Are you pregnant or planning to conceive? See antioxidant and fertility supplement guidance for context on prenatal micronutrient needs alongside iron.

Questions to ask your clinician or pharmacist:

  • What is my target ferritin level, and how long should I supplement to reach it?
  • Should I retest ferritin and hemoglobin at four to eight weeks?
  • At what point would you recommend switching to IV iron?
  • Does my current medication list require any separation from iron doses?

For broader guidance on selecting quality supplements, the supplement-selection framework at Fracture Club offers a useful third-party perspective on evaluating label claims and formulation quality.

Key Takeaways

Ferrous sulfate is the cost-effective first line for most people with iron deficiency; ferrous bisglycinate is the evidence-supported alternative when GI intolerance compromises adherence.

Point Details
Start with ferrous sulfate It is the low-cost, evidence-dense first line; use alternate-day dosing with vitamin C to reduce side effects.
Match elemental iron doses Always compare elemental iron content, not total chelate or tablet weight, when switching between formulations.
Bisglycinate for GI intolerance Switch to ferrous bisglycinate at a matched elemental dose if GI symptoms persist after a four-week ferrous sulfate trial.
Dose gap matters A substantially lower bisglycinate dose does not automatically match a higher ferrous sulfate dose; the Cambodia RCT confirmed this.
Nexoclub iron supplements Nexoclub stocks ferrous bisglycinate options with clear elemental iron labeling for readers who need a gentler oral iron.

The case for being deliberate about which iron you choose

Most of the confusion around iron supplements comes from treating “higher bioavailability” as a universal selling point. It is not. Bioavailability is only meaningful relative to the dose delivered and the population taking it. A chelated form at 18 mg elemental iron does not outperform 60 mg of ferrous sulfate simply because its absorption fraction is higher. The Cambodia trial made that clear.

What bisglycinate genuinely offers is a tolerability advantage that keeps people on therapy. That is not a minor point. Iron deficiency anemia requires months of consistent supplementation to fully replete stores. If GI side effects cause someone to stop at week three, the “most bioavailable” form in the world has failed. Tolerability is efficacy, measured over time.

The other underappreciated variable is dosing strategy. Alternate-day dosing, which reduces hepcidin-mediated suppression between doses, is one of the most evidence-supported changes in oral iron management in recent years. It applies to both formulations. Switching from daily ferrous sulfate to alternate-day ferrous sulfate often resolves GI complaints without requiring a more expensive chelated product at all.

My practical recommendation: try ferrous sulfate first, dosed every other day with vitamin C. Give it four weeks. If you are still struggling with constipation or nausea, move to bisglycinate at a matched elemental dose. Do not pay the 3–5x cost premium preemptively. And regardless of which form you choose, confirm your ferritin target with a clinician and retest at eight weeks. Supplementing without monitoring is guessing.

Nexoclub’s iron supplement selection for gentler daily support

Readers who have tried ferrous sulfate and found the GI side effects too disruptive have a clear next step: ferrous bisglycinate at a matched elemental dose. Nexoclub carries a curated selection of iron supplements, including ferrous bisglycinate options with transparent supplement facts panels that show elemental iron content clearly.

Nexoclub

When you shop the Nexoclub supplements and nutrition collection, look for the elemental iron figure on the supplement facts panel, not just the total chelate weight. A product listing “ferrous bisglycinate 126 mg” may deliver only 25 mg elemental iron; that is the number that matters for dosing. Nexoclub’s product descriptions include this detail so you can compare doses accurately before purchasing.

Browse the iron and nutritional supplement range at Nexoclub to find a bisglycinate option that fits your elemental iron target and budget.

This article provides general health information, not medical advice. Confirm your iron status with a blood test and discuss supplementation with a qualified clinician before starting or changing a regimen.

Selected sources and further reading

Back to blog